3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Smoldering Multiple Myeloma
1
Polyps
1
Peripheral Nervous System Diseases
1
Monoclonal Gammopathy of Undetermined Significance
1
Malnutrition
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Dyspareunia
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Breast Carcinoma In Situ
1
Interventions
Fluorouracil
87
Leucovorin
78
Oxaliplatin
77
Irinotecan
76
Bevacizumab
50
Cetuximab
42
Capecitabine
42
Panitumumab
17
Folfox protocol
16
Floxuridine
11
Chemotherapy, Adjuvant
11
regorafenib
10
IFL protocol
10
Nivolumab
9
Drug Therapy
9
trifluridine tipiracil drug combination
8
Surgical Procedures, Operative
8
Neoadjuvant Therapy
8
sargramostim
7
pembrolizumab
7
XELOX
7
Specimen Handling
7
Biopsy
7
Trastuzumab
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
HMPL-013
6
tislelizumab
5
encorafenib
5
Trifluridine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colonic Neoplasms
×
Fatty Acids, Omega-3
×
Clear all
NCT03661047
2021-11-17
OMICC
Massachusetts General Hospital
Phase 2
Withdrawn